ZA201606471B - Antimitotic amides for the treatment of cancer and proliferative disorders - Google Patents
Antimitotic amides for the treatment of cancer and proliferative disordersInfo
- Publication number
- ZA201606471B ZA201606471B ZA2016/06471A ZA201606471A ZA201606471B ZA 201606471 B ZA201606471 B ZA 201606471B ZA 2016/06471 A ZA2016/06471 A ZA 2016/06471A ZA 201606471 A ZA201606471 A ZA 201606471A ZA 201606471 B ZA201606471 B ZA 201606471B
- Authority
- ZA
- South Africa
- Prior art keywords
- antimitotic
- cancer
- treatment
- amides
- proliferative disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461942956P | 2014-02-21 | 2014-02-21 | |
| PCT/US2015/016928 WO2015127284A2 (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201606471B true ZA201606471B (en) | 2025-06-25 |
Family
ID=52684675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2016/06471A ZA201606471B (en) | 2014-02-21 | 2016-09-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10016398B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3107909B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6506313B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102420508B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114634483B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015218775C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016019161B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2940237C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2893374T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL247293B (cg-RX-API-DMAC7.html) |
| MX (1) | MX390530B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2713179C2 (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201606869TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015127284A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201606471B (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| CN114634483B (zh) | 2014-02-21 | 2024-08-13 | 弗洛斯特生物科技有限公司 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
| CN106727583A (zh) * | 2016-12-12 | 2017-05-31 | 范旭升 | 一种治疗舒张性心衰的药物组合物 |
| US11377436B2 (en) * | 2017-07-12 | 2022-07-05 | The Brigham And Women's Hospital, Inc. | EAAT2 enhancing molecules |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| KR20250173438A (ko) * | 2024-05-30 | 2025-12-10 | 삼진제약주식회사 | Nr2f6 억제제 및 이의 용도 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| CN1433413A (zh) * | 2000-06-05 | 2003-07-30 | 东亚制药株式会社 | 新的噁唑烷酮衍生物及其制备方法 |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| AU2005259488B2 (en) * | 2004-06-30 | 2009-10-01 | Novartis Ag | Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors |
| EP1921066A4 (en) * | 2005-08-11 | 2010-07-07 | Takeda Pharmaceutical | Pyridylphenol compound and its use |
| CA2640049A1 (en) * | 2006-01-31 | 2007-08-09 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
| EP2086966B1 (en) | 2006-11-17 | 2011-09-14 | GlaxoSmithKline LLC | 2-carboxy thiophene derivatives as anti viral agents |
| WO2008125839A2 (en) * | 2007-04-12 | 2008-10-23 | Piramed Limited | Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase |
| JP2012504603A (ja) * | 2008-10-01 | 2012-02-23 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連の使用のための化合物 |
| WO2010100475A1 (en) * | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| ES2528485T3 (es) * | 2009-09-11 | 2015-02-10 | Amgen, Inc | N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina para su uso en el tratamiento del cáncer resistente a agentes antimitóticos |
| WO2011139489A2 (en) * | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| WO2011142151A1 (ja) * | 2010-05-14 | 2011-11-17 | シャープ株式会社 | 携帯型情報端末およびその制御方法 |
| TWI541243B (zh) * | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| CN103380117A (zh) * | 2011-01-21 | 2013-10-30 | Abbvie公司 | 激酶的吡啶酰胺抑制剂 |
| CN103402985A (zh) * | 2011-02-10 | 2013-11-20 | 先正达参股股份有限公司 | 杀微生物的吡唑衍生物 |
| US9604978B2 (en) * | 2011-05-03 | 2017-03-28 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| CA2853485A1 (en) * | 2011-10-28 | 2013-05-02 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| CN114634483B (zh) * | 2014-02-21 | 2024-08-13 | 弗洛斯特生物科技有限公司 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
-
2015
- 2015-02-20 CN CN202210190090.XA patent/CN114634483B/zh active Active
- 2015-02-20 JP JP2016570919A patent/JP6506313B2/ja active Active
- 2015-02-20 CA CA2940237A patent/CA2940237C/en active Active
- 2015-02-20 CN CN201580009889.2A patent/CN106068263A/zh active Pending
- 2015-02-20 US US15/120,470 patent/US10016398B2/en active Active
- 2015-02-20 BR BR112016019161-7A patent/BR112016019161B1/pt active IP Right Grant
- 2015-02-20 AU AU2015218775A patent/AU2015218775C1/en active Active
- 2015-02-20 ES ES15710328T patent/ES2893374T3/es active Active
- 2015-02-20 EP EP15710328.4A patent/EP3107909B1/en active Active
- 2015-02-20 SG SG11201606869TA patent/SG11201606869TA/en unknown
- 2015-02-20 WO PCT/US2015/016928 patent/WO2015127284A2/en not_active Ceased
- 2015-02-20 KR KR1020167026016A patent/KR102420508B1/ko active Active
- 2015-02-20 RU RU2016135555A patent/RU2713179C2/ru active
- 2015-02-20 MX MX2016010877A patent/MX390530B/es unknown
- 2015-02-20 SG SG10202000590SA patent/SG10202000590SA/en unknown
-
2016
- 2016-08-16 IL IL247293A patent/IL247293B/en active IP Right Grant
- 2016-09-20 ZA ZA2016/06471A patent/ZA201606471B/en unknown
-
2018
- 2018-06-29 US US16/024,407 patent/US10772872B2/en active Active
-
2020
- 2020-09-03 US US17/011,589 patent/US11129813B2/en active Active
-
2021
- 2021-09-13 US US17/473,364 patent/US12383533B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| IL254720A0 (en) | Indoleamine 3,2-dioxygenase inhibitors for cancer treatment | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| NZ779654A (en) | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs | |
| NZ726723A (en) | Heteroaryl compounds for kinase inhibition | |
| PH12016501972A1 (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| PH12016502179A1 (en) | Inhibitors of lysine specific demethylase-1 | |
| EA201790766A1 (ru) | Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| TN2019000210A1 (en) | Antitumoral compounds | |
| PH12020551586A1 (en) | Oxysterols and methods of use thereof | |
| SA519402288B1 (ar) | مركب بيريميدين واستخداماته الصيدلانية | |
| ZA201606471B (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| TW201613864A (en) | Novel compounds | |
| PH12017500095A1 (en) | Imidazopyridazine compounds | |
| PH12015501588A1 (en) | Compounds and methods for treating bacterial infections | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA033423B1 (ru) | Циклопропанбензофуранилпиридопиразиндионы | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| JOP20190163B1 (ar) | منشط nrf2 | |
| NZ732704A (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| MY183757A (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases |